PRP treatment
Phase 2Biologic
PRP treatment is one of 64 biologic programs targeting Low back pain. It is currently in Phase 2.
2
Indications
2
Total Trials
1
Active Trials
63
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
778 competitors in Osteoarthritis
#DrugCompanyPhaseTrials
1Ilaris
NovartisPreclinical
Toradol
RochePreclinical
Voltaren
CCerimon Pharmaceuticals
Preclinical
Cataflam
NovartisPreclinical
Bayer Aspirin
BayerPreclinical
Enbrel
IImmunex
Preclinical
PRP treatment
RRegenexx, LLC
Phase 2
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Preclinical
Decadron
QQuince Therapeutics S.p.A.
Preclinical
Benadryl
PParkedale
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for PRP treatment. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 2[1]
- Company
- RRegenexx, LLC